Daiichi Sankyo Co : Daiichi Sankyo Receives Approval in Japan to Market RANMARK(R), a Treatment for Bone Complications Stemming from Multiple Myeloma and Bone Metastases from Solid Tumors

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department Telephone: [phone] (Public Relations)

[phone] (Investor Relations)

http://www.daiichisankyo.com/

Daiichi Sankyo Receives Approval in Japan to Market RANMARK